Medicon Valley Biomedical Newsletter

H. Lundbeck A/S has developed a drug, Siramesine, which was originally hoped to suppress anxiety. However, the drug turned out to be able to kill resistant cancer cells. This led to an unusual collabo...

A novel study from the Lund University has shown that information about current lifestyle and the genes can predict the risk of developing diabetes. The identification of candidate gen...

Active Biotech AB has commenced enrolment for a clinical Phase I combination study of its candidate drug, ANYARA, with the cancer drug, Taxotere. The study is designed to evaluate the two drugs in com...

Alligator Bioscience AB has signed of a collaboration agreement with a major European drug company for the optimisation of a protein, using Alligator's proprietary ssDNA recombination technology, ...

BoneSupport AB has been granted FDA approval for its first product, Cerament Bone Void Filler, a ceramic and injectable bone substitute used for among other things bone fractures caused by osteoporosi...

Gastrotech Pharma A/S has announced that DOR BioPharma, Inc. has signed a binding letter of intent to acquire Gastrotech Pharma A/S. Gastrotech develops therapeutics based on peptide hormones to treat...

Genmab A/S has announced that the US Patent and Trademark Office have issued a patent for HuMax-HepC. HuMax-HepC is a fully human antibody currently in pre-clinical development to prevent reinfection ...

LEO Pharma A/S and US-based GTC Biotherapeutics, Inc. have entered into a collaboration agreement to develop and market ATryn for markets in Europe, the Middle East, and Canada. ATryn is GTC's rec...

As part of the gaboxadol license, development and commercialisation agreement entered between H. Lundbeck A/S and a wholly-owned affiliate of Merck & Co., Inc. in February 2004, Lundbeck has annou...

MediCult A/S and Novo Nordisk A/S have signed an agreement whereby MediCult shall perform in vitro proof-of-concept studies, with the aim of proving the concept and identifying potential dose range. N...

In October 2005, the Boards of Directors of Chr. Hansen Holding A/S and ALK-Abelló A/S drew up a merger plan. In this connection, in an announcement to the Copenhagen Stock Exchange, Chr. Hansen Holdi...

Nordic Biotech Advisors ApS has announced the first closing of their second biotech fund - Nordic Biotech Venture Fund II K/S, NB II - with a committed capital of EUR 41,5 mill. A second closing is fo...

NsGene A/S has received a milestone payment from US-based Biogen Idec, Inc. in accordance with the advancement of the Neublastin development for the therapy of neuropathic pain. The development of Neu...

Pharmexa A/S has been awarded the DNB NORs Innovation Award, Denmark-Norway. The award of EUR 12,800 is a result of DnB NORs efforts to encourage innovation in the business community. The ministers of...

Rheoscience A/S and Indian-based Dr. Reddy's Laboratories have entered into a co-development and commercialization agreement for the joint development and commercialisation of balaglitazone, DRF 2593,...

Santaris Pharma A/S has announced that the FDA has approved an Investigational New Drug Application, IND, for the company's international Phase I/II study of SPC2996 in chronic lymphocytic leukaemia, ...

Merck KgaA has acquired Survac ApS for EUR 11 million to gain access to novel technologies for the treatment of cancer. The acquisition is expected to be completed this year. The founders of Su...

IKANO Investments, Sparbanken Finn, Innovationsbron Syd and Region Skåne are making an initial investment of EUR 5,3 million in the Venture Capital fund, Teknoseed II. With a broadened investor base, ...

TopoTarget A/S and US-based CuraGen Corporation have initiated the patient dosing in a Phase Ib open-label, multi-centre, proof-of-concept clinical trial evaluating PXD101, a small molecule histone de...

TopoTarget A/S has announced that patient dosing has started in one of two planned proof-of-concept Phase II trials to evaluate the HDAC, histone deacetylase, inhibitor, BACECA, as a novel topical tre...